SURESNES, Servier, an independent international pharmaceutical group governed by a foundation, and IDEAYA Biosciences, Inc., a leading precision medicine oncology company, unveiled an exclusive license agreement to bring darovasertib, a promising treatment for a rare eye cancer, to patients globally.
In this agreement, Servier obtains the regulatory and commercial rights for darovasertib in all territories outside the United States. IDEAYA retains its rights for darovasertib in the United States. Darovasertib, a potent and selective protein kinase C (PKC) inhibitor, is being developed to broadly address primary and metastatic uveal melanoma (UM).
Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need. IDEAYA will receive an upfront payment of USD 210 million and up to USD 320 million in regulatory and commercial milestones, plus double-digit royalties on net sales.
Darovasertib is currently being evaluated in multiple global clinical trials. These include a Phase 2/3 randomized trial evaluating darovasertib in combination with crizotinib in first line patients with HLA-A2-negative metastatic uveal melanoma (UM), for which the median progression free survival readout is anticipated from year-end 2025 to Q1 2026, and a Phase 3 randomized trial evaluating neoadjuvant darovasertib as a monotherapy in primary UM, independent of HLA status.
Executive Statement
According to Arnaud Lallouette, Executive Vice-President of Global Medical & Patient Affairs at Servier, at Servier, their mission is to deliver transformative therapies to patients with significant needs. Their collaboration with IDEAYA is a significant step to make darovasertib the potential first-in-class treatment available to uveal melanoma patients worldwide. There are limited treatment options, and there is an urgent need to improve patient outcomes. We look forward to leveraging their global oncology network and expertise in developing oncology-targeted therapies to make this groundbreaking treatment accessible to patients across the globe.